# Pizarra — PT-pseudo_d38917f87b35 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d38917f87b35
Task: 1

Encounter: Urology - outpatient on 11 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 61-year-old male
  - PSA: 28.3 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.4 ng/mL²
  - PSA velocity: -0.78 ng/mL/yr
  - Prior PSA: 25.3 ng/mL
  - Prostate volume: 70.0 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8709831 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes, Hypercholesterolaemia
  - Problem list / PMHx: Type 2 diabetes, Hypercholesterolaemia
  - Current medication: empagliflozin, simvastatin, rosuvastatin
  - Allergies: NKA
  - Additional notes: PSA 28.3 ng/mL. PI-RADS 5. PSAD 0.40. Prostate volume 70 mL. DRE nodus. csPCa 0.87.

Vitals: weight 99 kg, height 177 cm, BMI 31.6, BP 126/68 mmHg, HR 67 bpm. Smoking: Ex-smoker (23 pack-yr, quit 2015).

Chief complaint: Rising prostate-specific antigen levels to 28.3 ng/mL alongside a confirmed prior malignancy prompt this clinical review.

History: A 61-year-old retired firefighter initiated urological workup in mid-2023 after an elevated screening result, leading to a systematic biopsy that confirmed a Positive finding of ISUP GG5 disease. Currently residing with his partner as a widowed individual, the patient maintains a rigorous exercise regimen of three 5-kilometre runs per week. Lower urinary tract complaints have increased, pushing his IPSS score to 19 out of 35. Past medical records highlight well-managed type 2 diabetes under empagliflozin therapy, alongside hypercholesterolaemia addressed with simvastatin and rosuvastatin. He successfully ceased smoking after accumulating 23 pack-years, having quit in 2015. Additional surgical history includes a meniscectomy on the right knee performed during his firefighting career, and he recently finished a six-session physiotherapy course for mechanical back pain that remains independent of his urological status. An adult son handles his primary medical communications, and morning appointments are preferred to align with his public transit routine.

Physical examination: DRE: The prostate presents as asymmetrically enlarged, featuring a distinct, firm nodule within the left peripheral zone. Systemic assessment shows stable hemodynamics and a body mass index of 31.6. Abdominal palpation detects no masses, and cervical or inguinal lymph nodes remain non-palpable.

Patient info: retired firefighter; Widowed; Lives with partner.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 12 units / week; exercise Running 3x/week, 5 km; IPSS score: 19/35 (moderate LUTS).

Recent other appointments: Physiotherapy — lower back, six sessions.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.42 +/- 0.20   (95% CI 0.08-0.82)

Where the uncertainty comes from:
  - aleatoric  dA = 0.17  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 5.9 effective neighbours out of 10; 2 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=28.3, age=61.0, psad=0.4, dre_ord=1.0, vol=70.0, n_pmhx=2.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the visible panel data (PI-RADS=5, PSA=28.3, prior biopsy positive, csPCa probability=0.87) and failed to incorporate the crucial context of the retrieved documents, such as the specific MRI findings, PSA velocity (-0.78 ng/mL/yr), and the specific PSA density (0.4 ng/mL²).

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a wide uncertainty interval (0.42 +/- 0.20). This wide interval suggests the classifier cannot distinguish between the two outcomes, which is precisely what EXPERT-PROTOCOL noted: the panel is undetermined. The prior fails to account for the guideline criterion that requires reviewing the MRI prose and prior biopsy status to settle the decision.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - what is the trend beyond the headline value?
previous GP / urology notes - what context is provided regarding the prior positive diagnosis?
laboratory panel - what are the full lab results, especially PSA density?

GUIDELINE ANCHOR
The guideline search indicates that the decision depends on the MRI prose, prior biopsy status, and whether a repeat biopsy is warranted based on risk factors like PSA density and PI-RADS score.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_d38917f87b35", "radiology_report": "Radboudumc Radiology Service | 08 Jan 2025\nStudy: Multiparametric MRI of the Prostate\nIndication: Follow-up after a previously positive biopsy. Current prostate-specific antigen stands at 28.3.\n\nFindings: The gland occupies a total volume of 70.0 mL. A discrete abnormality localizes to the left peripheral zone, spanning the base through mid-gland, measuring roughly 28 mm longest diameter. T2 sequences highlight pronounced hypointensity within this focus. Diffusion-weighted techniques demonstrate marked restriction, mirrored by low apparent diffusion coefficient values. Post-contrast phases show prompt, localized enhancement compared to adjacent tissue. Seminal vesicles appear normal and symmetrical. Pelvic lymph nodes show no suspicious morphology, and capsular integrity remains intact without extracapsular spread.\n\nImpression: Left peripheral zone mass scoring PI-RADS 5. Calculated PSA density registers 0.4. Estimated csPCa probability computes to 0.8709831."}
get_psa_trend
{"case_id": "PT-pseudo_d38917f87b35", "psa_trend": [{"date": "Jul 2023", "val": 1.3}, {"date": "Dec 2023", "val": 19.1}, {"date": "Apr 2024", "val": 9.0}, {"date": "Aug 2024", "val": 9.7}, {"date": "Jan 2025", "val": 28.3}]}
get_previous_notes
{"case_id": "PT-pseudo_d38917f87b35", "previous_notes": [{"date": "16 May 2024", "author": "Dr. R. van den Berg (GP)", "text": "An April 2024 PSA draw returned 23.1 ng/mL, continuing the rising trend established since the initial biopsy confirmed a Positive result earlier in the calendar year. Clinical tracking focused on lower urinary tract symptom progression and overall health status."}, {"date": "17 Jan 2024", "author": "Dr. R. van den Berg (GP)", "text": "Following a December 2023 PSA measurement of 22.4 ng/mL, a consultation addressed the recent prostate cancer diagnosis and the significance of the earlier biopsy results. Discussion centered on the pathological features and general prognosis. Scheduled laboratory assessments and symptom tracking continued."}]}
get_lab_results
{"case_id": "PT-pseudo_d38917f87b35", "laboratory_results": [{"name": "PSA", "val": "28.3 ng/mL", "date": "02 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "3.22 ng/mL", "date": "02 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "11%", "date": "02 Dec 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "13.8 g/dL", "date": "02 Dec 2024", "flag": ""}, {"name": "WBC", "val": "6.2 x10^9/L", "date": "02 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "244 x10^9/L", "date": "02 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "90 umol/L", "date": "02 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "02 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "15.8 nmol/L", "date": "02 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "93 U/L", "date": "02 Dec 2024", "flag": ""}, {"name": "LDH", "val": "150 U/L", "date": "02 Dec 2024", "flag": ""}]}

NOT RETRIEVED
The family history of prostate cancer was not retrieved, which is not required for this decision.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5, lesion measuring 28 mm, with marked diffusion restriction.
- PSA trend: Rising trend from 1.3 ng/mL (Jul 2023) to 28.3 ng/mL (Jan 2025).
- Lab results: PSA density of 0.4 ng/mL² and %Free PSA of 11%.

AGAINST sampling this patient now:
- Previous notes: Patient is on a re-evaluation, and the prior biopsy confirmed ISUP GG5 disease.
- Previous notes: No explicit mention of a surveillance protocol or planned re-biopsy.

WHERE THIS LEANS
The high-risk MRI finding (PI-RADS 5) combined with a significant PSA rise and a high csPCa probability strongly argues for further tissue characterization, despite the prior diagnosis.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

Although the patient has a prior positive biopsy, the high PI-RADS 5 score and the significant PSA rise warrant further tissue characterization to guide definitive management. The retrieved evidence shows a PI-RADS 5 lesion measuring 28 mm and a PSA trend from 1.3 ng/mL to 28.3 ng/mL, which strongly argues for re-sampling. The prior notes do not document a surveillance protocol or a final ISUP grade, meaning the biopsy result is necessary to determine the next step in the treatment pathway.

Variables that carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
